Literature DB >> 35816214

[Implantation of mechanical circulatory support systems and heart transplantation in patients with end-stage heart failure : Consensus paper of the DGK, DGTHG].

P Christian Schulze1, Markus J Barten2, Udo Boeken3, Gloria Färber4, Christian M Hagl5, Christian Jung6, David Leistner7, Evgenij Potapov8, Johann Bauersachs9, Philip Raake10, Nils Reiss11, Diyar Saeed12, David Schibilsky13, Stefan Störk14, Christian Veltmann15, Andreas J Rieth16, Jan Gummert17.   

Abstract

The treatment of patients with advanced heart failure requires interdisciplinary care in a qualified heart failure team, especially prior to and in the follow-up of mechanical circulatory support (MCS) implantation and heart transplantation (HTx). The basic prerequisite is the early specialized evaluation of symptomatic patients even under optimized heart failure treatment. Diagnostics and treatment are initially aimed at improving the prognosis. If the prerequisites for MCS or HTx treatment are present, possible contraindications and problems have to be evaluated in order to achieve an optimal risk-benefit ratio for the abovementioned complex treatments with limited resources. The optimal treatment is still HTx if the conditions are right, so this should be sought in all potential patients. At the same time, the optimal individual transplantation window should not be missed. The provision of a MCS system is a treatment performed with very good results for patients with exclusion criteria for HTx or with hemodynamic instability that prevents a longer waiting time for a donor organ. Short-term and medium-term survival is now comparable to HTx when carefully indicated. Timely implantation before the onset of manifest end-organ damage is crucial. Optimized implementation of advanced treatment requires professional structures that enable effective interdisciplinary cooperation between different sectors of health care.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Advanced heart failure; End-organ damage; Heart transplantation; Low cardiac output syndrome; Mechanical circulatory support

Mesh:

Year:  2022        PMID: 35816214     DOI: 10.1007/s00063-022-00942-4

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   1.552


  36 in total

1.  Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry.

Authors:  Marco Canepa; Candida Fonseca; Ovidiu Chioncel; Cécile Laroche; Maria G Crespo-Leiro; Andrew J S Coats; Alexandre Mebazaa; Massimo F Piepoli; Luigi Tavazzi; Aldo P Maggioni
Journal:  JACC Heart Fail       Date:  2018-06       Impact factor: 12.035

2.  Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association.

Authors:  Biykem Bozkurt; Andrew J S Coats; Hiroyuki Tsutsui; Ca Magdy Abdelhamid; Stamatis Adamopoulos; Nancy Albert; Stefan D Anker; John Atherton; Michael Böhm; Javed Butler; Mark H Drazner; G Michael Felker; Gerasimos Filippatos; Mona Fiuzat; Gregg C Fonarow; Juan-Esteban Gomez-Mesa; Paul Heidenreich; Teruhiko Imamura; Ewa A Jankowska; James Januzzi; Prateeti Khazanie; Koichiro Kinugawa; Carolyn S P Lam; Yuya Matsue; Marco Metra; Tomohito Ohtani; Massimo Francesco Piepoli; Piotr Ponikowski; Giuseppe M C Rosano; Yasushi Sakata; Petar Seferović; Randall C Starling; John R Teerlink; Orly Vardeny; Kazuhiro Yamamoto; Clyde Yancy; Jian Zhang; Shelley Zieroth
Journal:  Eur J Heart Fail       Date:  2021-03-03       Impact factor: 15.534

3.  Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices.

Authors:  Daniel J Goldstein; Bart Meyns; Rongbing Xie; Jennifer Cowger; Stephen Pettit; Takeshi Nakatani; Ivan Netuka; Steven Shaw; Masanobu Yanase; James K Kirklin
Journal:  J Heart Lung Transplant       Date:  2019-04       Impact factor: 10.247

4.  Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study.

Authors:  Keyur B Shah; Randall C Starling; Joseph G Rogers; Douglas A Horstmanshof; James W Long; Vigneshwar Kasirajan; Josef Stehlik; Joyce Chuang; David J Farrar; Jerry D Estep
Journal:  J Heart Lung Transplant       Date:  2017-12-07       Impact factor: 10.247

Review 5.  Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology.

Authors:  Maria G Crespo-Leiro; Marco Metra; Lars H Lund; Davor Milicic; Maria Rosa Costanzo; Gerasimos Filippatos; Finn Gustafsson; Steven Tsui; Eduardo Barge-Caballero; Nicolaas De Jonge; Maria Frigerio; Righab Hamdan; Tal Hasin; Martin Hülsmann; Sanem Nalbantgil; Luciano Potena; Johann Bauersachs; Aggeliki Gkouziouta; Arjang Ruhparwar; Arsen D Ristic; Ewa Straburzynska-Migaj; Theresa McDonagh; Petar Seferovic; Frank Ruschitzka
Journal:  Eur J Heart Fail       Date:  2018-07-17       Impact factor: 15.534

6.  Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee.

Authors:  James C Fang; Gregory A Ewald; Larry A Allen; Javed Butler; Cheryl A Westlake Canary; Monica Colvin-Adams; Michael G Dickinson; Phillip Levy; Wendy Gattis Stough; Nancy K Sweitzer; John R Teerlink; David J Whellan; Nancy M Albert; Rajan Krishnamani; Michael W Rich; Mary N Walsh; Mark R Bonnell; Peter E Carson; Michael C Chan; Daniel L Dries; Adrian F Hernandez; Ray E Hershberger; Stuart D Katz; Stephanie Moore; Jo E Rodgers; Joseph G Rogers; Amanda R Vest; Michael M Givertz
Journal:  J Card Fail       Date:  2015-05-04       Impact factor: 5.712

7.  INTERMACS profiles of advanced heart failure: the current picture.

Authors:  Lynne Warner Stevenson; Francis D Pagani; James B Young; Mariell Jessup; Leslie Miller; Robert L Kormos; David C Naftel; Karen Ulisney; Patrice Desvigne-Nickens; James K Kirklin
Journal:  J Heart Lung Transplant       Date:  2009-06       Impact factor: 10.247

8.  Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Tiana Nizamic; M Hassan Murad; Larry A Allen; Colleen K McIlvennan; Sara E Wordingham; Daniel D Matlock; Shannon M Dunlay
Journal:  JACC Heart Fail       Date:  2018-07-11       Impact factor: 12.035

9.  INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry.

Authors:  Michelle M Kittleson; Palak Shah; Anuradha Lala; Rhondalyn C McLean; Salpy Pamboukian; Douglas A Horstmanshof; Jennifer Thibodeau; Keyur Shah; Jeffrey Teuteberg; Nisha A Gilotra; Wendy C Taddei-Peters; Thomas M Cascino; Blair Richards; Shokoufeh Khalatbari; Neal Jeffries; Lynne W Stevenson; Douglas Mann; Keith D Aaronson; Garrick C Stewart
Journal:  J Heart Lung Transplant       Date:  2019-08-28       Impact factor: 10.247

10.  Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology.

Authors:  Giuseppe M C Rosano; Brenda Moura; Marco Metra; Michael Böhm; Johann Bauersachs; Tuvia Ben Gal; Stamatis Adamopoulos; Magdy Abdelhamid; Vasiliki Bistola; Jelena Čelutkienė; Ovidiu Chioncel; Dimitrios Farmakis; Roberto Ferrari; Gerasimos Filippatos; Loreena Hill; Ewa A Jankowska; Tiny Jaarsma; Pardeep Jhund; Mitja Lainscak; Yuri Lopatin; Lars H Lund; Davor Milicic; Wilfried Mullens; Fausto Pinto; Piotr Ponikowski; Gianluigi Savarese; Thomas Thum; Maurizio Volterrani; Stefan D Anker; Petar M Seferovic; Andrew J S Coats
Journal:  Eur J Heart Fail       Date:  2021-05-20       Impact factor: 17.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.